According to the Zhitong Finance App, Cinda Biotech (01801.HK) issued an announcement regarding the global strategic cooperation between Cinda Biotech and Takeda Pharmaceuticals (through Takeda Pharmaceuticals International AG, a wholly-owned subsidiary of Takeda Pharmaceuticals), and that all prerequisites for each licensing, option and cooperation agreement and share issuance agreement have been reached or exempted (if applicable). As a result, the licensing, option and cooperation agreement was completed, and the share issuance agreement was completed on December 4, 2025.

According to the Zhitong Finance App, Cinda Biotech (01801.HK) issued an announcement regarding the global strategic cooperation between Cinda Biotech and Takeda Pharmaceuticals (through Takeda Pharmaceuticals International AG, a wholly-owned subsidiary of Takeda Pharmaceuticals), and that all prerequisites for each licensing, option and cooperation agreement and share issuance agreement have been reached or exempted (if applicable). As a result, the licensing, option and cooperation agreement was completed, and the share issuance agreement was completed on December 4, 2025.